If you're interested in investing in the massive consumer health market, Kenvue (KVUE -1.07%) stock could be just what you're looking for. Spun off from Johnson & Johnson (JNJ 0.29%), Kenvue first started trading in public markets in May 2023.
It's now the company behind many of the most popular consumer health products, taking over major brands that were previously part of Johnson & Johnson. In this guide, you'll learn how to invest in Kenvue, how the company is performing so far, and whether it's a good investment.
Stock
How to buy
How to buy Kenvue stock
Since Kenvue is a publicly traded company, investing in it is a straightforward process. Here's a step-by-step breakdown of how to buy Kenvue stock.
- Open your brokerage app: Log in to your brokerage account where you handle your investments.
- Search for the stock: Enter the ticker or company name into the search bar to bring up the stock's trading page.
- Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
- Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
- Submit your order: Confirm the details and submit your buy order.
- Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.
Should I invest?
Should I invest in Kenvue?
Kenvue is best suited for investors who want to prioritize safety over growth. It has an excellent portfolio of well-known brands, it's in good shape financially, and it pays a sizable dividend. But it certainly won't match the kinds of highs the top growth stocks reach.
While Kenvue hasn't been available long, it's not an unproven new company. After all, it was previously part of Johnson & Johnson, which has frequently ranked as one of the largest companies by market cap. Now that it's on its own, Kenvue is a major player among consumer goods companies and is the largest pure-play consumer health company.
Even if you don't know much about Kenvue as a company, you're probably familiar with many of its brands. They include:
- Band-Aid.
- Johnson's.
- Listerine.
- Neutrogena.
- Neosporin.
- Nicorette.
- Tylenol.
- Zyrtec.
Because its brands are fairly diversified, Kenvue has a reliable business model that consistently churns out a profit. It's also not overly reliant on any one market. It generates about 50% of its sales in North America and 50% internationally.
The downside to investing in Kenvue is that it's probably not going to grow too significantly. Its brands have established, well-known product lines with a fairly fixed demand. These brands also have stiff competition from white-labeled (generic) products that provide similar quality at more affordable prices.
To Kenvue's credit, it's working on expanding its product offerings by embracing new technology. It launched Neutrogena® Collagen Bank™ in August 2024, a new skincare line aimed at younger consumers. It also announced a five-year collaboration with Microsoft (MSFT -0.28%) in April 2025 to transform its digital operations using artificial intelligence (AI) technology. However, Kenvue stock is still more of a low-risk investment than a potential home run.
Profitability
Is Kenvue profitable?
Kenvue is a profitable company. In 2024, it reported $1 billion in net income on revenue of $15.5 billion. However, profitability has been declining; net income fell from $1.7 billion in 2023 and $2.1 billion in 2022.
Dividends
Does Kenvue pay a dividend?
Yes, Kenvue pays a quarterly dividend of $0.205 per share as of 2025. It has a high dividend yield and has increased its dividend every year so far.
Kenvue will likely operate similarly to Johnson & Johnson in terms of its dividends. Johnson & Johnson has consistently ranked as one of the best dividend stocks, raising its dividend for more than six decades. While Kenvue is relatively new, it's already following the same approach.
ETF options
ETFs with exposure to Kenvue
If you want to build out your portfolio more quickly, ETFs that hold Kenvue stock are another option. Instead of owning Kenvue stock directly, you would get to invest in Kenvue as part of an ETF containing a number of stocks. Here are a few of the ETFs with significant exposure to Kenvue:
- The Consumer Staples Select Sector SPDR Fund (XLP 0.47%) aims to provide an effective representation of the consumer staples sector of the S&P 500. Along with Kenvue, other major holdings include Costco Wholesale (COST 0.25%), Walmart (WMT 1.45%), and Procter & Gamble (PG 0.78%).
- The Renaissance IPO ETF (IPO 2.56%) invests in newly listed companies. It's rebalanced each quarter to add new initial public offerings (IPOs), and stocks are cycled out three years after their IPOs, so Kenvue will be one of its holdings until 2026.
- The ProShares S&P 500 Dividend Aristocrats ETF (NOBL 0.46%) seeks to track the performance of the S&P 500 Dividend Aristocrats® Index. It's built around companies that pay high dividends, so if that's what attracted you to Kenvue, this ETF could be a good choice for a more diverse portfolio of dividend stocks.
Exchange-Traded Fund (ETF)
Stock splits
Will Kenvue stock split?
There’s no indication that Kenvue will announce a stock split. Considering the company had its IPO in May 2023 and trades at an affordable share price, it's unlikely to have any upcoming stock splits in the near future. Johnson & Johnson has gone through six stock splits over the years, but its most recent happened in 2001.
Related investing topics
The bottom line on Kenvue
Since Kenvue stock is available on public markets, you can buy shares through any brokerage account. If you'd prefer an all-in-one investment with more stocks, you could buy shares of an ETF with exposure to Kenvue, such as one of the many consumer staples ETFs.
As an investment, there's a lot to like about Kenvue stock. It's stable, profitable, and has a large roster of well-known brands. It's a solid choice if you're looking for security and a healthy quarterly dividend.
FAQ
Investing in Kenvue FAQ
Is Kenvue worth investing in?
Kenvue is worth investing in if you're looking for stable value stocks to add to your portfolio. It's also a good choice for dividend investors because it offers a high dividend yield.
What happens to Johnson & Johnson stock after the Kenvue split?
Johnson & Johnson is now solely a medical device and pharmaceutical company, and its stock provides investors with exposure to those markets. Kenvue handles the consumer health business. Shareholders of Johnson & Johnson were given the option to swap their shares for Kenvue stock. The offer expired in August 2023.
What is the outlook for Kenvue?
Analysts have a reasonably positive outlook for Kenvue stock, expecting it to grow a moderate amount over the next year and on a long-term basis.
